Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling
Tingting Qin, Zhujun Liu, Jing Wang, Junling Xia, Shaochuan Liu, Yanan Jia, Hailin Liu, Kai Li
Abstract
Anlotinib inhibits lymphangiogenesis and lymphatic metastasis, probably through inactivating VEGFR-3 phosphorylation. The results indicate that anlotinib may be beneficial for treatment in avoiding lymphangiogenesis and distant lymphatic metastasis in lung adenocarcinoma. (Trial registration: ALTER0303; NCT02388919; March 17, 2015.).
Topics & Concepts
LymphangiogenesisLymphatic EndotheliumCancer researchLymphatic systemVEGF receptorsMetastasisLungAdenocarcinomaMedicineInternal medicinePathologyCancerLymphatic System and DiseasesVascular Tumors and AngiosarcomasAngiogenesis and VEGF in Cancer